The Texas Research Park is currently composed of many organizations whose work involves various stages of the very complicated drug development process. Researchers at The University of Texas Institute of Biotechnology/Department of Molecular Medicine are making tremendous advances in breast cancer gene research. The Institute for Drug Development is dedicated to the discovery and development of new and unique anticancer agents and conducts preclinical studies which result in innovative drug candidates for advancement into clinical trials. The Southwest Oncology Group staff coordinates cancer treatments and chemoprevention studies conducted by a network of more than 3,600 registered physicians. ILEX Oncology is dedicated to accelerating the development of drugs for cancer treatment by managing clinical trials, preparing registrations, and developing manufacturing processes. GeneTex, Inc. is developing new products needed for basic and preclinical research.

Institutions in the Texas Research Park are part of a larger alliance of organizations whose scientists are dedicated to developing and translating research into improved health care and cure of disease. The economic impact on the Texas Research Park is substantial and engenders exponential growth of the local economy. The network of scientists in the Texas Research Park creates a synergy that has a profound, immeasurable impact on society. The founding fathers' vision is becoming a reality.